GlassScriptPhysician profile
Francis Peter Nicholson
NPI 1003816166
$375.55
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.70 · 2021: $242 · 2022: $61.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $97.41 | 2021-2022 | |
| Pfizer INC. | $43.22 | 2019 | |
| Endo Pharmaceuticals INC. | $34.92 | 2021 | |
| Janssen Biotech, INC. | $32.70 | 2021 | |
| Astellas Pharma US INC | $24.69 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $23.89 | 2021 | |
| Coloplast Corp | $23.44 | 2021 | |
| Merck Sharp & Dohme LLC | $21.09 | 2021 | |
| Amgen INC. | $16.91 | 2021 | |
| Baxter Healthcare | $15.69 | 2019 | |
| 180 Medical, INC. | $15.31 | 2021 | |
| Boston Scientific Corporation | $13.79 | 2019 | |
| Acerus Pharmaceuticals Corporation | $12.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.